January 06, 2014
Teva Pharmaceuticals USA Inc. and Boehringer Ingelheim Pharmaceuticals Inc. were hit Monday with another proposed antitrust class action, this in Minnesota federal court, over an alleged pay-for-delay deal that kept a generic form of an anti-stroke medication off the market.